Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in KRSA held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Kalehua Capital Management LLC | 1.7M | $5.6M | β | 35.040% | 1.79% |
| 2 | FMR LLC | 650K | $2.2M | +13603.5% | 13.783% | 0.00% |
| 3 | BALYASNY ASSET MANAGEMENT L.P. | 318K | $1.1M | β | 6.737% | 0.00% |
| 4 | ADAR1 Capital Management, LLC | 299K | $1.0M | β | 6.339% | 0.05% |
| 5 | BRAIDWELL LP | 157K | $532K | β | 3.329% | 0.02% |
| 6 | CITADEL ADVISORS LLC | 60K | $203K | +227.5% | 1.269% | 0.00% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 46K | $155K | -45.8% | 0.973% | 0.00% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 31K | $105K | +91.6% | 0.656% | 0.00% |
| 9 | Rangeley Capital, LLC | 24K | $82K | β | 0.516% | 0.08% |
| 10 | BlackRock, Inc. | 17K | $57K | 0.0% | 0.356% | 0.00% |
| 11 | DIMENSIONAL FUND ADVISORS LP | 12K | $40K | β | 0.249% | 0.00% |
| 12 | VANGUARD FIDUCIARY TRUST CO | 7K | $25K | 0.0% | 0.156% | 0.00% |
| 13 | UBS Group AG | 3K | $11K | -7.5% | 0.067% | 0.00% |
| 14 | Tower Research Capital LLC (TRC) | 2K | $6K | β | 0.039% | 0.00% |
| 15 | GROUP ONE TRADING LLC | 192 | $651 | 0.0% | 0.004% | 0.00% |
| 16 | OSAIC HOLDINGS, INC. | 130 | $440 | 0.0% | 0.003% | 0.00% |
| 17 | Activest Wealth Management | 100 | $339 | 0.0% | 0.002% | 0.00% |
| 18 | BARCLAYS PLC | 87 | $295 | β | 0.002% | 0.00% |
| 19 | WHI TRUST Co LLC | 72 | $244 | 0.0% | 0.002% | 0.00% |
| 20 | HRT FINANCIAL LP | 22K | $74 | β | 0.468% | 0.00% |
| 21 | BNP PARIBAS FINANCIAL MARKETS | 4 | $14 | -20.0% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in KRSA β a direct measure of their conviction.
Filings activity in KRSA during Q2 2026, grouped by how each filer changed its position.
No institutions trimmed their position this quarter.
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 21 | +24% | 69.99% | +66.56 pp | $11M | +4360% |
| Q1 2026 | 17 | 11% | 3.43% | 2.90 pp | $0M | 34% |
| Q4 2025 | 19 | +19% | 6.33% | 25.85 pp | $0M | 24% |
| Q3 2025 | 16 | 11% | 32.18% | 22.07 pp | $0M | 53% |
| Q2 2025 | 18 | 5.3% | 54.25% | 1.58 pp | $1M | +13% |
| Q1 2025 | 19 | +0.0% | 55.83% | 1.28 pp | $1M | 24% |
| Q4 2024 | 19 | +19% | 57.11% | 98.80 pp | $1M | 54% |
| Q3 2024 | 16 | β | 155.91% | β | $3M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying KRSA stock.
Based on Q2 2026 13F filings, institutional ownership of Korsana Biosciences, Inc. stands at 70.0%, held across 21 reporting institutions.
Kalehua Capital Management LLC is the largest reported institutional holder of KRSA, with approximately 1,651,350 shares worth $0.01B as of Q2 2026.
Yes β 1 widely-followed marquee investor appear among the top 25 institutional holders of KRSA, including CITADEL ADVISORS LLC.
Our composite Smart Money Score for KRSA is 62 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
8 institutions opened new positions in KRSA during Q2 2026, while 5 fully exited. 12 added to existing positions and 0 trimmed.
KRSA institutional ownership rose by 66.56 percentage points quarter-over-quarter, with a net change of +4 holders.
The top 10 institutions account for 99.2% of all reported 13F value in KRSA, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Korsana Biosciences, Inc. (KRSA) Institutional Ownership